PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis
USA - NASDAQ:PCRX - US6951271005 - Common Stock
23.78 USD
+0.16 (+0.68%)
23.78 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to PCRX. PCRX was compared to 192 industry peers in the Pharmaceuticals industry. While PCRX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. PCRX has a bad growth rate and is valued cheaply. This makes PCRX very considerable for value investing!
1. Profitability
1.1 Basic Checks
PCRX had positive earnings in the past year.
In the past year PCRX had a positive cash flow from operations.
Of the past 5 years PCRX 4 years were profitable.
Each year in the past 5 years PCRX had a positive operating cash flow.
1.2 Ratios
PCRX has a Return On Assets of 1.65%. This is amongst the best in the industry. PCRX outperforms 83.25% of its industry peers.
The Return On Equity of PCRX (2.95%) is better than 83.25% of its industry peers.
PCRX's Return On Invested Capital of 3.63% is amongst the best of the industry. PCRX outperforms 81.68% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 15.35%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
PCRX has a Profit Margin of 2.99%. This is amongst the best in the industry. PCRX outperforms 81.68% of its industry peers.
PCRX's Operating Margin of 8.88% is amongst the best of the industry. PCRX outperforms 82.20% of its industry peers.
PCRX's Operating Margin has improved in the last couple of years.
PCRX's Gross Margin of 79.17% is amongst the best of the industry. PCRX outperforms 84.29% of its industry peers.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
PCRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, PCRX has less shares outstanding
PCRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PCRX has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.04 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.04, PCRX is in the better half of the industry, outperforming 63.87% of the companies in the same industry.
PCRX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as PCRX would need 3.03 years to pay back of all of its debts.
PCRX has a Debt to FCF ratio of 3.03. This is amongst the best in the industry. PCRX outperforms 89.53% of its industry peers.
A Debt/Equity ratio of 0.52 indicates that PCRX is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.52, PCRX is not doing good in the industry: 61.78% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 2.04 |
ROIC/WACC0.48
WACC7.59%
2.3 Liquidity
PCRX has a Current Ratio of 5.26. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.26, PCRX is doing good in the industry, outperforming 69.63% of the companies in the same industry.
A Quick Ratio of 3.78 indicates that PCRX has no problem at all paying its short term obligations.
PCRX has a better Quick ratio (3.78) than 61.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
The earnings per share for PCRX have decreased by -6.90% in the last year.
PCRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.96% yearly.
Looking at the last year, PCRX shows a very negative growth in Revenue. The Revenue has decreased by -16.85% in the last year.
The Revenue has been growing by 10.73% on average over the past years. This is quite good.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
Based on estimates for the next years, PCRX will show a small growth in Earnings Per Share. The EPS will grow by 5.92% on average per year.
The Revenue is expected to grow by 5.45% on average over the next years.
EPS Next Y-8.75%
EPS Next 2Y1.59%
EPS Next 3Y6.02%
EPS Next 5Y5.92%
Revenue Next Year5.37%
Revenue Next 2Y7.75%
Revenue Next 3Y8.09%
Revenue Next 5Y5.45%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 8.01, the valuation of PCRX can be described as very reasonable.
Based on the Price/Earnings ratio, PCRX is valued cheaper than 92.67% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.89, PCRX is valued rather cheaply.
A Price/Forward Earnings ratio of 7.18 indicates a rather cheap valuation of PCRX.
93.72% of the companies in the same industry are more expensive than PCRX, based on the Price/Forward Earnings ratio.
PCRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.01 | ||
| Fwd PE | 7.18 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaply inside the industry as 92.67% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, PCRX is valued cheaper than 91.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.6 | ||
| EV/EBITDA | 7.07 |
4.3 Compensation for Growth
The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.57
EPS Next 2Y1.59%
EPS Next 3Y6.02%
5. Dividend
5.1 Amount
No dividends for PCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23.78
+0.16 (+0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners116.55%
Inst Owner Change-0.55%
Ins Owners0.81%
Ins Owner Change0.59%
Market Cap1.07B
Revenue(TTM)716.79M
Net Income(TTM)21.44M
Analysts76.92
Price Target38.15 (60.43%)
Short Float %13.48%
Short Ratio10.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)0%
PT rev (3m)-4.1%
EPS NQ rev (1m)-0.13%
EPS NQ rev (3m)-2.27%
EPS NY rev (1m)0.84%
EPS NY rev (3m)-1.04%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)-0.83%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.01 | ||
| Fwd PE | 7.18 | ||
| P/S | 1.49 | ||
| P/FCF | 8.6 | ||
| P/OCF | 7.55 | ||
| P/B | 1.47 | ||
| P/tB | 3.29 | ||
| EV/EBITDA | 7.07 |
EPS(TTM)2.97
EY12.49%
EPS(NY)3.31
Fwd EY13.93%
FCF(TTM)2.76
FCFY11.62%
OCF(TTM)3.15
OCFY13.24%
SpS15.95
BVpS16.19
TBVpS7.22
PEG (NY)N/A
PEG (5Y)0.57
Graham Number32.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROCE | 5.34% | ||
| ROIC | 3.63% | ||
| ROICexc | 4.58% | ||
| ROICexgc | 7.99% | ||
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% | ||
| FCFM | 17.33% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.44 | ||
| Cap/Depr | 18.95% | ||
| Cap/Sales | 2.4% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 91.52% | ||
| Profit Quality | 579.36% | ||
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 2.04 |
F-Score7
WACC7.59%
ROIC/WACC0.48
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
EPS Next Y-8.75%
EPS Next 2Y1.59%
EPS Next 3Y6.02%
EPS Next 5Y5.92%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
Revenue Next Year5.37%
Revenue Next 2Y7.75%
Revenue Next 3Y8.09%
Revenue Next 5Y5.45%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year0.19%
EBIT Next 3Y7.79%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What are the PE and PB ratios of PACIRA BIOSCIENCES INC (PCRX) stock?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 8.01 and the Price/Book (PB) ratio is 1.47.
What is the financial health of PACIRA BIOSCIENCES INC (PCRX) stock?
The financial health rating of PACIRA BIOSCIENCES INC (PCRX) is 6 / 10.